US Patent Issued to Terns Pharmaceuticals on Dec. 2 for "Combinations of GLP-1R and THRBeta agonists and methods of use thereof" (California Inventors)

ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,485,118, issued on Dec. 2, was assigned to Terns Pharmaceuticals Inc. (Foster City, Calif.).

"Combinations of GLP-1R and THRBeta agonists and methods of use thereof" was invented by Christopher T. Jones (Walnut Creek, Calif.), Jeffrey R. Jasper (Mountain View, Calif.), Olivia D. Teal (Cardiff, Calif.) and Kevin P. Quinn (San Mateo, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are combinations comprising a glucagon-like peptide-1 receptor (GLP-1R) agonist and a thyroid hormone receptor beta (THRBeta) agonist and methods comprising administering to a subject in need thereof such combinations."

The patent was filed on March 6, 2025...